Article
High levels of AXL expression in untreated EGFR-mutated non-small cell lung cancer negatively impacts the use of osimertinib.
Cancer science - 1 Feb 2023
Yoshimura Akihiro, Yamada Tadaaki, Serizawa Masakuni, Uehara Hisanori, Tanimura Keiko, Okuma Yusuke, Fukuda Akito, Watanabe Satoshi, Nishioka Naoya, Takeda Takayuki, Chihara Yusuke, Takemoto Shinnosuke, Harada Taishi, Hiranuma Osamu, Shirai Yukina, Shukuya Takehito, Nishiyama Akihiro, Goto Yasuhiro, Shiotsu Shinsuke, Kunimasa Kei, Morimoto Kenji, Katayama Yuki, Suda Kenichi, Mitsudomi Tetsuya, Yano Seiji, Kenmotsu Hirotsugu, Takahashi Toshiaki, Takayama Koichi
Abstract excerpt
For non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations, the initial therapeutic interventions will have crucial impacts on their clinical outcomes. Drug tolerant factors reportedly have an impact on EGFR-tyrosine kinase inhibitor sensitivity. This prospective study investigated the impacts of drug tolerant-related protein expression in tumors based on the efficacy...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.